Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
Please note the ANZCTR will be unattended on Monday the 7th of October for the Labour Day public holiday.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623000104651
Ethics application status
Approved
Date submitted
8/11/2022
Date registered
30/01/2023
Date last updated
20/11/2023
Date data sharing statement initially provided
30/01/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
Phase I Trial of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours
Query!
Scientific title
Phase I Trial of the Safety and Efficacy of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours
Query!
Secondary ID [1]
308235
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
DART (Deflexifol At Relapse Trial)
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Central Nervous System Tumour
327992
0
Query!
Ependymoma
327993
0
Query!
Diffuse Midline Glioma
327994
0
Query!
Diffuse Intrinsic Pontine Glioma
327995
0
Query!
Condition category
Condition code
Cancer
325050
325050
0
0
Query!
Children's - Brain
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This is a phase I multicentre study evaluating the use of Deflexifol in the treatment of children and young adults (greater than 12 months and less than or equal to 21 years) with refractory/recurrent central nervous system (CNS) tumours.
Deflexifol is a novel bioequivalent formulation of 5-fluorouracil and leucovorin that has been shown to be safe and effective in adults with advanced/ refractory solid tumours.
Phase I (or Part A) will be open to any participant with refractory or recurrent CNS tumours or diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG) after upfront radiotherapy. It will evaluate the safety profile and recommended phase II dose (RP2D) of deflexifol in participants with refractory/recurrent CNS tumours, or participants with newly diagnosed DIPG/DMG who have completed radiotherapy.
Deflexifol will be administered on Days 1 and 15 of a 28 day cycle. Deflexifol will initially be administered via an injection over 3-5 minutes (bolus), followed by a continuous intravenous infusion over 46 hours (infusional). Depending on the treating doctor and each participant’s condition, the treating doctor may elect to continue the treatment at home or in hospital. The following four dose levels will be tested, starting dose is Dose level 0:
Dose level -2: Deflexifol bolus dose of 525mg/m2 and infusional dose of 2400mg/m2 over 46 hours
Dose level -1: Deflexifol bolus dose of 525mg/m2 and infusional dose of 3000mg/m2 over 46 hours
Dose level 0: Deflexifol bolus dose of 525mg/m2 and infusional dose of 3400mg/m2 over 46 hours
Dose level +1: Deflexifol bolus dose of 525mg/m2 and infusional dose of 3800mg/ m2 over 46 hours
Each participant will be assigned a dose level at the start of treatment and will remain at the dose for the duration of the study. Participants may receive a minimum of 1 dose of study drug and a maximum of one year of study drug, as long as the participant is able to tolerate treatment.
Dosing will follow a dose de-escalation or escalation scheme which will be determined by biological effect of the drug (measured in participant blood samples) and levels of toxicity (measured by dose limiting toxicity and adverse event observed). A recommended phase 2 dose (RP2D) will be determined in this Phase I study.
Query!
Intervention code [1]
324691
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
332874
0
Frequency, severity and relatedness of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including dose-limiting toxicities (DLTs), in children and young adults receiving deflexifol. Adverse events will be assessed via clinical examination and are graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Query!
Assessment method [1]
332874
0
Query!
Timepoint [1]
332874
0
Dose limiting toxicities (DLTs) are defined as any events that are possibly, probably or definitely attributable to deflexifol in the first 4 weeks of treatment (Cycle 1). Therefore DLT evaluation will be performed in Cycle 1. Treatment emergent adverse events (TEAEs) and severe adverse events (SAEs) will be monitored continuously during the 1 year treatment.
Query!
Secondary outcome [1]
414926
0
Identify the maximum tolerated dose (MTD) of deflexifol in paediatrics by presence of dose limiting toxicities during Cycle 1.
Query!
Assessment method [1]
414926
0
Query!
Timepoint [1]
414926
0
Dose limiting toxicities will be assessed and graded using the CTCAE v5.0 for the first 4 weeks of treatment (Cycle 1).
Query!
Secondary outcome [2]
414927
0
Identify the recommended phase 2 dose (RP2D) of deflexifol in paediatrics through assessment of adverse events (AEs). The paediatric RP2D will be based on the findings of the toxicity and activity profile in patients enrolled in this study.
Query!
Assessment method [2]
414927
0
Query!
Timepoint [2]
414927
0
AEs will be assessed through clinical assessment and graded using the CTCAE v5.0 every 2 weeks.
Query!
Eligibility
Key inclusion criteria
1. Written informed consent
2. Patients must be greater than 12 months and less than or equal to 21 years of age at the time of study enrolment
3. Patient must have histologic confirmation of CNS tumour that is refractory or recurrent based on radiologic or tissue diagnosis; and for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.
4. Patient must have measurable disease as per RAPNO criteria and/or evaluable disease. For patients who have received prior radiation therapy, the irradiated lesion needs to have progressed since cessation of radiotherapy.
5. Karnofsky performance status greater than or equal to 50 for patients above 16 years old;; or Lansky performance status greater than or equal to 50 for patients less than or equal to 16 years old. Patients who are not able to walk due to paralysis, but who are sitting up in a wheelchair, are considered ambulatory for the purpose of performance score assessment
6. Life expectancy of greater than 6 weeks
7. Patients receiving corticosteroids will need to be on a stable, or reducing, dose of steroids for at least one week before enrolment
8. Fully recovered from acute toxic effects of all prior anti-cancer therapy
8a. Must not have received myelosuppressive chemotherapy within 21 days of study entry (42 days if prior nitrosourea or mitomycin-C)
8b. At least 7 days after the last dose of anti-cancer agents not known to be myelosuppressive. For agents that have known adverse events occurring beyond 7 days after last administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair
8c. At least 42 days after the completion of any type of immunotherapy, e.g. tumour vaccines
8d. At least 21 days after the last dose of a monoclonal antibody, and toxicities related to prior antibody therapy have recovered to less than or equal to grade 1
8e. At least 6 weeks after the completion of radiation therapy (including CSI). If palliative radiotherapy has been administered, then 2 weeks must have lapsed before the patient can commence on this trial, and this lesion cannot be used as the target lesion for assessment of treatment response
8f. 14 days or more from last long-acting haematopoietic growth factors (e.g. pegfilgrastim) or 7 days for short acting growth factor
9. Adequate function in bone marrow, renal and liver. Blood pressure within normal range for age
10. Patient must be or have been previously enrolled in the ZERO Childhood Cancer (ZERO) precision medicine trial or program
11. Female patient of childbearing potential must have a negative serum or urine pregnancy test at screening and prior to the beginning of each cycle. They must agree to use an effective method of contraception during the study period and for six months after treatment discontinuation
12. Fertile male patients must use an effective method of contraception during the study period and for six months after treatment discontinuation
Query!
Minimum age
12
Months
Query!
Query!
Maximum age
21
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Concomitant medications
1a. Patients who are currently receiving another investigational agent are not eligible
1b. Patients who are currently receiving other anti-cancer agents are not eligible
2. Any known Dihydropyrimidine dehydrogenase (DPD) deficiency
3. Prior solid organ transplantation
4. Uncontrolled infection
5. Pregnant or breastfeeding
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
A rolling 6 design will be used to enrol a minimum of 6 patients and maximum of 24 patients. The rolling six trial design will be used for dose finding. Enrolment will be suspended after the first patient has been enrolled until completion of the DLT period. Following that, 2 to 6 patients can be concurrently enrolled onto a dose level, dependent upon: number of patients enrolled on the current dose level; number of patients who have experienced DLT at the current dose level; number of patients entered, but without tolerability data at the current dose level.
Analysis plan:
RAPNO criteria will be tabulated for each evaluation time point and for each dose level.
The incidence of all AEs and SAEs will be summarised separately for treatment groups by system organ class and preferred term. Additionally, the incidence of all AEs and SAEs will be summarised by severity and relationship to study treatment. Patients who terminate the study due to an AE will be listed.
Safety data (haematology, serum chemistry and vital signs) will be summarised with simple descriptive statistics (minimum, maximum and median).
A Statistical Analysis Plan (SAP) details the statistical evaluations. This is based on:
- Descriptive statistics for safety data (outlined above) based on each dose level
- PK analysis, per dose level, and anthropometric measures (height, weight, body surface area using the Mosteller formula)
- Preliminary efficacy analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
1/04/2023
Query!
Actual
29/08/2023
Query!
Date of last participant enrolment
Anticipated
31/03/2025
Query!
Actual
Query!
Date of last data collection
Anticipated
31/03/2030
Query!
Actual
Query!
Sample size
Target
24
Query!
Accrual to date
1
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC
Query!
Recruitment hospital [1]
23409
0
Sydney Children's Hospital - Randwick
Query!
Recruitment hospital [2]
23410
0
The Children's Hospital at Westmead - Westmead
Query!
Recruitment hospital [3]
23411
0
John Hunter Children's Hospital - New Lambton
Query!
Recruitment hospital [4]
23412
0
The Royal Childrens Hospital - Parkville
Query!
Recruitment hospital [5]
23413
0
Monash Children’s Hospital - Clayton
Query!
Recruitment hospital [6]
23414
0
Queensland Children's Hospital - South Brisbane
Query!
Recruitment hospital [7]
23415
0
Perth Children's Hospital - Nedlands
Query!
Recruitment hospital [8]
23416
0
Womens and Childrens Hospital - North Adelaide
Query!
Recruitment postcode(s) [1]
38809
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
38810
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
38811
0
2305 - New Lambton
Query!
Recruitment postcode(s) [4]
38812
0
3052 - Parkville
Query!
Recruitment postcode(s) [5]
38813
0
3168 - Clayton
Query!
Recruitment postcode(s) [6]
38814
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [7]
38816
0
5006 - North Adelaide
Query!
Recruitment postcode(s) [8]
38815
0
6009 - Nedlands
Query!
Funding & Sponsors
Funding source category [1]
312487
0
Charities/Societies/Foundations
Query!
Name [1]
312487
0
Kids with Cancer Foundation
Query!
Address [1]
312487
0
Unit 22, 22 Hudson Avenue, Castle Hill NSW 2154
Query!
Country [1]
312487
0
Australia
Query!
Funding source category [2]
312488
0
Charities/Societies/Foundations
Query!
Name [2]
312488
0
Robert Connor Dawes Foundation
Query!
Address [2]
312488
0
39 Royal Avenue, Sandringham, VIC 3191
Query!
Country [2]
312488
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
Australian and New Zealand Children’s Haematology and Oncology Group (ANZCHOG)
Query!
Address
27-31 Wright Street, Clayton VIC 3168
Query!
Country
Australia
Query!
Secondary sponsor category [1]
314078
0
None
Query!
Name [1]
314078
0
Query!
Address [1]
314078
0
Query!
Country [1]
314078
0
Query!
Other collaborator category [1]
282516
0
Individual
Query!
Name [1]
282516
0
Dr Marion Mateos - Co-Principal Investigator
Query!
Address [1]
282516
0
Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick NSW 2031
Query!
Country [1]
282516
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
311827
0
Sydney Children’s Hospitals Network Human Research Ethics Committee
Query!
Ethics committee address [1]
311827
0
Corner Hawkesbury Road and Hainsworth Street, Westmead NSW 2145
Query!
Ethics committee country [1]
311827
0
Australia
Query!
Date submitted for ethics approval [1]
311827
0
Query!
Approval date [1]
311827
0
10/08/2022
Query!
Ethics approval number [1]
311827
0
Query!
Summary
Brief summary
This is a multicentre Phase I clinical trial to establish if Deflexifol is safe and effective in children, adolescents and young adults with recurrent or refractory brain tumours. Who is it for? Participants may be eligible for this study if they are older than 12 months and up to 21 years old and have a recurrent or refractory brain tumour; or newly diagnosed diffuse intrinsic pontine glioma (DIPG) or diffuse midline glioma (DMG) participants after completion of radiotherapy. Study details Participants will receive Deflexifol every 2 weeks for up to approximately one year, if there is ongoing clinical benefit. Deflexifol will be administered via an injection over 3-5 minutes (bolus), followed by a continuous intravenous infusion over 46 hours. Pharmacokinetics will be measured during the first 4 weeks and safety will be assessed throughout the course of treatment and during follow up visits. Participants will have physical examinations, blood tests, urine tests, echocardiogram, electrocardiogram (ECG) and MRI scans. This study will test the safety and effectiveness of this new drug in children and adolescents in cases where treatment options are limited.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
122510
0
Prof David Ziegler
Query!
Address
122510
0
Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick NSW 2031
Query!
Country
122510
0
Australia
Query!
Phone
122510
0
+61 2 9382 1730
Query!
Fax
122510
0
Query!
Email
122510
0
d.ziegler@unsw.edu.au
Query!
Contact person for public queries
Name
122511
0
Robyn Strong
Query!
Address
122511
0
ANZCHOG, Hudson Institute of Medical Research, 27-31 Wright St, Clayton VIC 3168
Query!
Country
122511
0
Australia
Query!
Phone
122511
0
+613 8572 2684
Query!
Fax
122511
0
Query!
Email
122511
0
robyn.strong@hudson.org.au
Query!
Contact person for scientific queries
Name
122512
0
David Ziegler / Dr Marion Mateos
Query!
Address
122512
0
Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick NSW 2031
Query!
Country
122512
0
Australia
Query!
Phone
122512
0
+61 2 9382 1730
Query!
Fax
122512
0
Query!
Email
122512
0
SCHN-DART@health.nsw.gov.au
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Aggregate results will be made available publicly.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF